The anticonvulsant valproic acid (VPA, 2-n-propylpentanoic acid) causes inhibition of the citric acid cycle and elevations of central nervous system (CNS) "y-aminobutyric acid (GABA) levels, which correlates with anticonvulsant action. No unifying mechanism for these actions of VPA has won general acceptance. a-Ketoglutarate dehydrogenase complex (KDHC) is a critical control enzyme in the CNS. We hypothesized that VPA may be an inhibitor of this enzyme since decreased KDHC activity would reduce substrate flux through the citric acid cycle and may increase flux into GABA synthesis. To test this hypothesis, inhibition of purified beef brain KDHC by VPA and its metabolites 2-n-propylpent-2-enoic acid (A2,3 VPE) and their coenzyme A (CoA) derivatives were studied. Preincubation of the NADH-reduced enzyme with A2,3 VPE, VPA-CoA, and A2,3 VPE-CoA caused time-dependent inactivation, reversible by addition of CoA. Under steady-state conditions, A2,3 VPE and VPA-CoA were competitive inhibitors of KDHC and A2,3 VPE-CoA was a mixed inhibitor. These observations have implications for the molecular mechanisms of VPA action. VPA derivatives cause inactivation and inhibition of KDHC, which may explain the anticonvulsant and some toxic actions of VPA. (J. Clin. Invest. 1990Invest. 86:1574Invest. -1581 
Introduction
Valproic acid (VPA1; 2-n-propylpentanoic acid) is a branch chain fatty acid with anticonvulsant properties in humans and animals (1) . VPA disorders, but its use is limited by its toxicity, which may be severe or occasionally fatal (2) . Better understanding of the mechanisms of anticonvulsant and toxic actions of this drug might enable them to be separated and improved drugs designed. Since the biochemical toxicity of VPA resembles that seen in Reye's syndrome and certain inborn errors of metabolism, better understanding of VPA biochemistry might also provide some general insights into the mitochondrial dysfunction common to these conditions.
The anticonvulsant action of VPA is correlated with increased y-aminobutyric acid (GABA) levels in the central nervous system (CNS) of VPA-treated rats (3) . The mechanism of this GABA-elevating action is incompletely understood (4) .
VPA administration leads to increased incorporation of '4C-labeled glucose into GABA via the citric acid cycle (5) but the enzymatic site at which this occurs is not known. A clue to the possible site of action comes from the observations of that VPA is also an inhibitor of the mitochondrial citric acid cycle (6) (7) (8) (9) . A candidate single site for both of these VPA actions is a-ketoglutarate dehydrogenase complex (KDHC) (EC 1.2.4.2, 2.3.1.61, 1.6.4.3). The activity of this multienzyme complex is probably rate-limiting for citric acid cycle activity in CNS (10) and its substrate, a-ketoglutarate, can be utilized directly for GABA synthesis through glutamate (i 1). We hypothesized that VPA or VPA derivatives may be inhibitors of KDHC, since KDHC activity would lead to the observed inhibition of the citric acid cycle and could account for increased shunting of carbon skeletons into glutamate and GABA. Previously published data showing that oxygen utilization by rat liver mitochondria is inhibited by VPA if glutamate is a substrate (12) , but not if GABA or succinate are substrates (13) , suggests that the locus of VPA-mediated inhibition of the citric acid cycle is proximal to succinyl-CoA (12, 13) and is also consistent with our hypothesis.
In order to test the proposed inhibition of KDHC, we decided to examine VPA and pertinent metabolites in kinetic studies with the purified beef brain enzyme. Because there is evidence that tissue isoenzymes of KDHC may exist (14) , we chose to study the brain enzyme, although KDHC from other tissues has been extensively characterized (15) . A new method for purifying this enzyme was required because KDHC is present in relatively low concentration in the CNS (10) and the high lipid content of brain may impair its stability. Inhibition studies were performed with VPA and its major monounsaturated metabolite A2,3 valproenic acid (2-n-propylpent-2-enoic acid, A2,3 VPE) and their coenzyme A (CoA) esters. Ito et al. (16) have shown that VPA-CoA, which is present in rat liver during administration of VPA, is oxidized to A2,3 VPE-CoA by a-methylbutyryl-CoA dehydrogenase. A2,3 VPE was studied because anticonvulsant activity is better correlated with its plasma and tissue levels than the parent molecule (17, 18 Preparation of beef brain mitochondria. Two beef brains were chilled immediately after slaughter and trimming. The brains were diced in chilled isotonic buffer (50 mM Tris, 0.25 M sucrose, 2.7 mM EDTA, pH 7.4) and homogenized by six passes in a 500-ml glass-teflon homogenizer. The final volume was about 1.5 liter. The homogenate was centrifuged for 5 min at 3,000 g and the supernatant was retained. The pellet was rehomogenized and centrifuged as above. The combined supernatants were centrifuged at 17,000 g for 10 min. To rupture synaptosomes, the pellet was suspended in hypotonic buffer containing 6 mM Tris, 2.7 mM EDTA, pH 7.4, and quickly hand homogenized in a final volume of 250 ml. The preparation was centrifuged for 10 min at 17,000 g, the supernatant was discarded, and this step was repeated on the pellet. To remove excess lipid, the sedimented mitochondria were taken up in 100 ml of the isotonic buffer and carefully layered in aliquots on Ficoll 7% (wt/wt, in isotonic buffer). The aliquots were centrifuged at 1 1,500 g for 30 min. The resulting pellet, which now had a pronounced brown color, was used as the source of mitochondria.
Brain mitochondria were taken up in 400 ml of buffer containing 50 mM 3-[N-morpholino]propanesulfonic acid (MOPS), 3% Triton X-100 (vol/vol), 2.7 mM EDTA, 1 mM benzamidine, 1 (27) using distilled tetrahydrofuran as the solvent for preparation ofthe anhydrides. CoA esters were partially purified by filtration on a DEAE-cellulose column using a gradient of LiCl (0.01-0.25 M) in 6 mM HCI to elute. After desalting on a 2 X 45-cm Sephadex G-10 column and eluting with water, the product was adsorbed onto a 1.1 X 1.3-cm C18 Sep-pak cartridge (Waters Associates, Milford, MA), previously equilibrated successively with Table II . In these conditions, the enzymatic properties of the preparation from beef brain are similar to those previously reported in other tissues (19, (34) (35) (36) (37) .
Inactivation ofKDHC by VPA metabolites. Preincubation of KDHC (0.1 mg/ml) with 2 mM A2,3 VPE at 250C caused significant time-dependent loss of catalytic activity (P < 0.005) (Fig. 4) , but VPA up to 20 mM showed no inactivation. 0.1 mg/ml KDHC was used since more dilute solutions were less stable and activity too low for accurate assay. Inhibitor concentrations were 10-100-fold their steady-state Km to ensure saturating conditions. Attempts to reactivate the enzyme by extensive dialysis at 4VC failed, whereas control activity was unaffected by dialysis. Preincubation of NADH-reduced KDHC with both VPA-CoA and A2,3 VPE-CoA caused similar significant inactivation when incubated for up to 120 min (P < 0.001) (Fig. 5) (Fig. 6 A) . Under these conditions, Ki. was 41±1.3 MM. The Hill coefficient (Fig. 6 B) (Fig. 7 A) tics of a mixed type inhibitor (Fig. 7 B) (Fig. 9) . The metabolic effects of VPA in vivo resemble those seen in some inherited disorders of metabolism. Experiments were therefore performed to compare kinetic properties of some naturally occurring keto-acyl CoAs with those of the VPA metabolites. These experiments are summarized in Table III . The esters examined all showed marked inhibition of KDHC. All showed characteristics of competitive inhibitors with respect to CoA, except isobutyryl-CoA which was a mixed inhibitor (Fig. 1O) and showed kinetic properties similar to those of A2,3 VPE-CoA. Isobutyryl-CoA is known to be a suicide inhibitor which inactivates KDHC, presumably owing to covalent modification of the E2 subunit (19) .
Discussion
The results reported here are consistent with a proposed mechanism of VPA action in which inhibition and/or inactivation of KDHC by VPA would reduce citric acid cycle flux and increase flux into GABA synthesis. We have demonstrated that KDHC from mammalian brain is inactivated and inhibited by VPA metabolites. Chronic administration of VPA in therapeutic doses in dogs produced brain tissue levels of A2,3 VPE of -0.5-2 ,gM and VPA was considerably higher (38) .
Furthermore, VPA and its metabolites have been shown to accumulate 10-fold in mitochondria (39) . Although data describing steady-state intramitochondrial concentrations of CoA metabolites of VPA are lacking, even a conservative estimate based upon this published data suggests that they are present in concentrations well above the measured apparent Ki values as determined by us. In addition, inactivation ofKDHC by unsaturated VPA derivatives could provide a theoretic basis for the prolonged action of VPA (40) (41) (42) and be consistent with correlation of clinical effect with serum levels of unsaturated metabolites. During therapy, inactivation ofenzyme and its resynthesis or reactivation would be in a steady state, at a lower KDHC concentration than before treatment. After discontinuation of therapy, previous KDHC levels would only return after new synthesis and clearing ofprotein bound inhibitor. A precedent for inactivation by a similar molecule is isobutyryl-CoA, which is a known suicide inhibitor of KDHC (19) . This compound is elevated in disorders ofpropionate and methylmalonic acid metabolism, conditions whose clinical and biochemical complications are very similar to VPA toxicity.
The results reported here demonstrating inactivation of KDHC by VPA metabolites have implications for the molecular mechanism of such inactivation. A2,3 VPE inactivated KDHC whereas the saturated parent compound VPA did not. Since it is known that double bonds in A2,3 unsaturated acids are susceptible to nucleophilic attack (for example, during the chemical synthesis of unsaturated fatty acyl-CoA esters [27] ), it is possible that such a mechanism could explain the difference in behavior of the two molecules, although alternative possibilities such as allosteric effects are not excluded. Tight, probably covalent binding to the enzyme is supported by the fact that dialysis failed to reactivate it. Reduction ofFe(CN) 3, which is carried out by the El subunit, a-ketoglutarate decarboxylase, was not inhibited by A2,3 VPE, whereas NAD' reduction was inhibited. This observation suggests that binding of A2,3 VPE to KDHC is not at the El subunit.
The mechanism of inactivation of KDHC by VPA-CoA and A2,3 VPE-CoA was investigated by testing the possibility that these compounds bind to the reduced E2 subunit via a thioester bond, in a similar manner to its physiological product, succinyl-CoA:
0.000'.
-0.100-. In addition to inactivation, we have also demonstrated that VPA metabolites and some naturally occurring fatty acylCoAs are potent (reversible) inhibitors of KDHC. Inhibition of KDHC, which occurs in isolated rat hepatocytes under conditions favoring an increased acyl-CoA/free CoA ratio, is associated with reduced citric acid cycle flux (43-45). An increased acyl-CoA/free CoA ratio occurs in the presence of excess acyl groups, such as in patients with organic acidemias and other inborn errors of metabolism, and VPA therapy (46) . Although our studies do not directly address the relative importance in vivo of inactivation and inhibition, the similarity of the kinetics of VPA metabolites and natural acyl-CoA esters present in excess in inborn errors supports the notion that inhibition of the citric acid cycle and KDHC by VPA may be a significant effect in vivo.
The work presented here provides a testable model for VPA action. Experiments to analyze GABA flux from the brain cell body and synaptosomic mitochondria treated with VPA are currently under way to study this model further.
